By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – VisionGate today announced it has raised $1.96 million in the first tranche of a financing round and forged two collaborations to evaluate its automated 3D cell imaging platform for the early detection of lung cancer.

The $1.96 million tranche is part of a targeted $3 million equity round and will be used for further clinical development of its technology. Participants included undisclosed new and existing investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.